DOP2010000053A - Derivados de pirrolidin -2-ona como moduladores del receptor de androgeno - Google Patents
Derivados de pirrolidin -2-ona como moduladores del receptor de androgenoInfo
- Publication number
- DOP2010000053A DOP2010000053A DO2010000053A DO2010000053A DOP2010000053A DO P2010000053 A DOP2010000053 A DO P2010000053A DO 2010000053 A DO2010000053 A DO 2010000053A DO 2010000053 A DO2010000053 A DO 2010000053A DO P2010000053 A DOP2010000053 A DO P2010000053A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- pirrolidin
- ona
- derivatives
- receiver modulators
- androgen
- Prior art date
Links
- 239000003098 androgen Substances 0.000 title 1
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007205966 | 2007-08-07 | ||
| JP2007299658 | 2007-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2010000053A true DOP2010000053A (es) | 2010-07-15 |
Family
ID=40329363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2010000053A DOP2010000053A (es) | 2007-08-07 | 2010-02-05 | Derivados de pirrolidin -2-ona como moduladores del receptor de androgeno |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US7834051B2 (https=) |
| EP (1) | EP2176220B1 (https=) |
| JP (1) | JP5292390B2 (https=) |
| KR (1) | KR20100049644A (https=) |
| CN (1) | CN101821235B (https=) |
| AR (1) | AR067823A1 (https=) |
| AU (1) | AU2008284662B2 (https=) |
| BR (1) | BRPI0814957B8 (https=) |
| CA (1) | CA2695852C (https=) |
| CL (1) | CL2008002313A1 (https=) |
| CO (1) | CO6160326A2 (https=) |
| CR (1) | CR11266A (https=) |
| CY (1) | CY1114067T1 (https=) |
| DK (1) | DK2176220T3 (https=) |
| DO (1) | DOP2010000053A (https=) |
| EA (1) | EA017429B1 (https=) |
| ES (1) | ES2406685T3 (https=) |
| GE (1) | GEP20125571B (https=) |
| HR (1) | HRP20130374T1 (https=) |
| JO (1) | JO2864B1 (https=) |
| MA (1) | MA31639B1 (https=) |
| ME (1) | ME01579B (https=) |
| MX (1) | MX2010001484A (https=) |
| MY (1) | MY159910A (https=) |
| NZ (1) | NZ583624A (https=) |
| PE (1) | PE20090899A1 (https=) |
| PL (1) | PL2176220T3 (https=) |
| PT (1) | PT2176220E (https=) |
| RS (1) | RS52812B (https=) |
| SI (1) | SI2176220T1 (https=) |
| TN (1) | TN2010000062A1 (https=) |
| TW (1) | TWI418543B (https=) |
| WO (1) | WO2009020234A2 (https=) |
| ZA (1) | ZA201001289B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2176220T3 (pl) * | 2007-08-07 | 2013-08-30 | Takeda Pharmaceuticals Co | Pochodne pirolidyn-2-onu jako modulatory receptora androgenowego |
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| ES2488990T3 (es) * | 2008-02-22 | 2014-09-01 | Radius Health, Inc. | Moduladores selectivos del receptor de andrógenos |
| WO2009119880A1 (en) * | 2008-03-26 | 2009-10-01 | Takeda Pharmaceutical Company Limited | Substituted pyrazole derivatives and use thereof |
| MX338831B (es) | 2010-02-04 | 2016-05-03 | Radius Health Inc | Moduladores selectivos de receptores de androgenos. |
| EP2568806B1 (en) | 2010-05-12 | 2016-05-11 | Radius Health, Inc. | Therapeutic regimens |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
| WO2013152170A1 (en) * | 2012-04-04 | 2013-10-10 | Catylix, Inc. | Selective androgen receptor modulators |
| EP3378472A1 (en) | 2012-08-09 | 2018-09-26 | Dynamis Therapeutics, Inc. | Combinations of meglumine |
| US9868905B2 (en) | 2012-09-21 | 2018-01-16 | Merck Patent Gmbh | Compounds having a C—C triple bond and use thereof in liquid-crystal mixtures |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| FI3834824T3 (fi) | 2014-03-28 | 2025-12-05 | Univ Duke | Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla |
| KR101597327B1 (ko) * | 2014-04-24 | 2016-02-24 | 동아에스티 주식회사 | 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제 |
| CN103951688B (zh) * | 2014-05-06 | 2016-04-20 | 成都安斯利生物医药有限公司 | 一种制备3,5-二氟-4-甲基苯硼酸的方法 |
| LT3474841T (lt) | 2016-06-22 | 2022-06-10 | Ellipses Pharma Ltd | Ar+ krūties vėžio gydymo būdai |
| KR102707399B1 (ko) | 2017-01-05 | 2024-09-13 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
| IL279853B2 (en) | 2018-07-04 | 2025-01-01 | Radius Pharmaceuticals Inc | Polymorphic forms of RAD 1901-2HCL |
| JP7446316B2 (ja) | 2019-01-11 | 2024-03-08 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換ピロリジンアミドｉｉｉ |
| CN113348163B (zh) | 2019-02-12 | 2024-10-08 | 雷迪厄斯制药公司 | 方法和化合物 |
| CN110204505B (zh) * | 2019-05-31 | 2023-02-03 | 荆门医药工业技术研究院 | (s)-3-苄氧羰基-4-异丙基-2,5-恶唑烷二酮的制备工艺 |
| US20230012570A1 (en) * | 2019-11-20 | 2023-01-19 | Medshine Discovery Inc. | Bicyclic compound used as selective androgen receptor modulator |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4141399A1 (de) | 1991-12-16 | 1993-06-17 | Bayer Ag | 4-(substituierte)amino-3-arylpyrrolinon-derivate |
| ES2300151T3 (es) * | 1998-09-22 | 2008-06-01 | Astellas Pharma Inc. | Derivados de cianofenilo. |
| US6258833B1 (en) | 1999-12-23 | 2001-07-10 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| US7547728B2 (en) | 2001-12-06 | 2009-06-16 | University Of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
| US7026500B2 (en) | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
| JP2002088073A (ja) | 2000-09-08 | 2002-03-27 | Yamanouchi Pharmaceut Co Ltd | 抗アンドロゲン剤 |
| FR2817472B1 (fr) | 2000-12-06 | 2003-01-03 | Oreal | Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre |
| EP1466902A4 (en) | 2001-12-28 | 2005-11-09 | Takeda Pharmaceutical | ANTAGONISTS OF THE ANDROGEN RECEPTOR |
| JP4316232B2 (ja) | 2001-12-28 | 2009-08-19 | 武田薬品工業株式会社 | アンドロゲン受容体拮抗剤 |
| GEP20074191B (en) | 2002-06-17 | 2007-09-10 | Univ Tennessee Res Foundation | N-bridged selective androgen receptor modulators and methods of use thereof |
| BR0313405A (pt) | 2002-08-12 | 2005-07-12 | Takeda Pharmaceutical | Compostos, métodos para preparar um composto e para prevenir e/ou tratar câncer, prodroga, medicamento, modulador do receptor de androgênio, agente para prevenir e/ou tratar hipogonadismo ou pertubação climatérica masculina, osteoporose e câncer, e, uso de um composto |
| GB0402492D0 (en) | 2004-02-04 | 2004-03-10 | Pfizer Ltd | Pharmaceutically active compounds |
| US8519158B2 (en) * | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| EP1747193A1 (en) * | 2004-05-11 | 2007-01-31 | Pfizer Products Incorporated | Benzonitrile derivatives to treat musculoskeletal frailty |
| CA2566942A1 (en) | 2004-05-17 | 2005-12-08 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
| ATE552235T1 (de) | 2004-06-07 | 2012-04-15 | Univ Tennessee Res Foundation | Selektive androgen-rezeptor-modulator und anwendungsverfahren dafür |
| NZ555974A (en) | 2005-01-10 | 2010-11-26 | Acadia Pharm Inc | Aminophenyl derivatives as selective androgen receptor modulators |
| TW200724139A (en) | 2005-05-05 | 2007-07-01 | Warner Lambert Co | Androgen modulators |
| DK1891038T3 (da) | 2005-05-13 | 2009-01-19 | Lilly Co Eli | Substituerede n-arylpyrrolidiner som selektive androgenreceptormodulatorer |
| EP1911743B8 (en) | 2005-08-01 | 2013-01-16 | Takeda Pharmaceutical Company Limited | Cyclic amine compound |
| EP1987827A1 (en) | 2006-02-20 | 2008-11-05 | Takeda Pharmaceutical Company Limited | Novel pharmaceutical |
| CA2658098A1 (en) * | 2006-07-19 | 2008-01-24 | Osurf | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof |
| KR20090034395A (ko) | 2006-07-26 | 2009-04-07 | 노파르티스 아게 | 운데카프레닐 피로포스페이트 합성효소의 억제제 |
| CA2670976C (en) | 2006-11-30 | 2015-01-27 | Atsushi Hasuoka | Cyclic amine compound |
| PL2176220T3 (pl) | 2007-08-07 | 2013-08-30 | Takeda Pharmaceuticals Co | Pochodne pirolidyn-2-onu jako modulatory receptora androgenowego |
-
2008
- 2008-08-06 PL PL08792430T patent/PL2176220T3/pl unknown
- 2008-08-06 ES ES08792430T patent/ES2406685T3/es active Active
- 2008-08-06 HR HRP20130374AT patent/HRP20130374T1/hr unknown
- 2008-08-06 US US12/221,739 patent/US7834051B2/en active Active
- 2008-08-06 GE GEAP200811715A patent/GEP20125571B/en unknown
- 2008-08-06 DK DK08792430.4T patent/DK2176220T3/da active
- 2008-08-06 RS RS20130235A patent/RS52812B/sr unknown
- 2008-08-06 SI SI200830941T patent/SI2176220T1/sl unknown
- 2008-08-06 ME MEP-2013-64A patent/ME01579B/me unknown
- 2008-08-06 US US12/672,516 patent/US8420694B2/en not_active Expired - Fee Related
- 2008-08-06 KR KR1020107005062A patent/KR20100049644A/ko not_active Abandoned
- 2008-08-06 MX MX2010001484A patent/MX2010001484A/es active IP Right Grant
- 2008-08-06 CL CL2008002313A patent/CL2008002313A1/es unknown
- 2008-08-06 NZ NZ583624A patent/NZ583624A/en not_active IP Right Cessation
- 2008-08-06 CN CN2008801105925A patent/CN101821235B/zh not_active Expired - Fee Related
- 2008-08-06 BR BRPI0814957A patent/BRPI0814957B8/pt not_active IP Right Cessation
- 2008-08-06 EP EP08792430A patent/EP2176220B1/en active Active
- 2008-08-06 CA CA2695852A patent/CA2695852C/en active Active
- 2008-08-06 AR ARP080103428A patent/AR067823A1/es unknown
- 2008-08-06 AU AU2008284662A patent/AU2008284662B2/en not_active Ceased
- 2008-08-06 PT PT87924304T patent/PT2176220E/pt unknown
- 2008-08-06 TW TW097129774A patent/TWI418543B/zh not_active IP Right Cessation
- 2008-08-06 PE PE2008001314A patent/PE20090899A1/es not_active Application Discontinuation
- 2008-08-06 EA EA201070246A patent/EA017429B1/ru unknown
- 2008-08-06 MY MYPI2010000564A patent/MY159910A/en unknown
- 2008-08-06 WO PCT/JP2008/064500 patent/WO2009020234A2/en not_active Ceased
- 2008-08-06 JP JP2010504096A patent/JP5292390B2/ja not_active Expired - Fee Related
- 2008-08-09 JO JO2008353A patent/JO2864B1/en active
-
2010
- 2010-02-05 TN TNP2010000062A patent/TN2010000062A1/fr unknown
- 2010-02-05 DO DO2010000053A patent/DOP2010000053A/es unknown
- 2010-02-12 CR CR11266A patent/CR11266A/es unknown
- 2010-02-23 ZA ZA2010/01289A patent/ZA201001289B/en unknown
- 2010-02-26 MA MA32657A patent/MA31639B1/fr unknown
- 2010-03-05 CO CO10026475A patent/CO6160326A2/es unknown
-
2013
- 2013-06-21 CY CY20131100507T patent/CY1114067T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2010000053A (es) | Derivados de pirrolidin -2-ona como moduladores del receptor de androgeno | |
| MX378735B (es) | Moduladores de receptores de quimiocina | |
| UY32469A (es) | Composiciones y metodos para modular la senda de señalizacion de wnt | |
| BR112018010118A2 (pt) | inibidores de cxcr2 | |
| EA201791359A1 (ru) | Конъюгаты, связывающие белок-лекарственное средство, содержащие производные антрациклина | |
| EA201071201A1 (ru) | ИНДОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ НИКОТИНОВОГО РЕЦЕПТОРА АЦЕТИЛХОЛИНА ПОДТИПА α-71 | |
| WO2012093809A3 (en) | New bicyclic compound for modulating g protein-coupled receptors | |
| AU2011232516A8 (en) | Chemical compounds | |
| EA201300887A1 (ru) | Модуляторы s1p | |
| EA201270465A1 (ru) | Новейшие модуляторы | |
| PH12015502546B1 (en) | 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient | |
| EA201590954A1 (ru) | Дигидропиразольные модуляторы gpr40 | |
| EA201590951A1 (ru) | Дигидропиразольные модуляторы gpr40 | |
| CR20120204A (es) | Nuevo uso antitumoral de cabazitaxel | |
| EA201590949A1 (ru) | Дигидропиразольные модуляторы gpr40 | |
| CO6491037A2 (es) | Derivados de pirazinooxazepina | |
| CR20110581A (es) | Preparación de solido | |
| AR103317A1 (es) | Moduladores de ciclopropil dihidrobenzofurano de receptores de melatonina | |
| AR103355A1 (es) | Moduladores de ciclopropanocarboxamida del regulador de conductancia transmembrana de la fibrosis quística | |
| EA201300513A1 (ru) | Волокна для контролируемого разложения | |
| MX2015015906A (es) | Mejoras en o con relacion a compuestos organicos. | |
| ECSP13012535A (es) | Compuesto heterocíclico y sus usos | |
| CR20110275A (es) | 3-aminociclopentancarboxamidas como moduladores del receptor quimiocina | |
| UY34072A (es) | Derivados sustituidos de indol | |
| UY32711A (es) | Nueva forma cristalina de pemirolast |